Results 71 to 80 of about 1,326 (158)

Myelinoclastic diffuse sclerosis (Schilder’s disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures

Journal of Neuroinflammation, 2019
Background Myelinoclastic diffuse sclerosis (MDS; also termed Schilder’s disease) is a rare inflammatory demyelinating disorder of the central nervous system characterised by demyelination of vast areas of the white matter. It is unclear whether MDS is a
S. Jarius, J. Haas, F. Paul, B. Wildemann   +3 more
doaj   +1 more source

Letter on “Real‐World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell‐Based Assay”

Annals of Clinical and Translational Neurology, Volume 12, Issue 11, Page 2376-2377, November 2025.
Raveena Vij, Alexander J. Jonokuchi, Ilya Kister   +2 more
wiley   +1 more source

Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS

European Journal of Neurology, Volume 32, Issue 2, February 2025.
ABSTRACT Background Relapsing–remitting (RR) and primary progressive (PP) multiple sclerosis (MS) have distinct clinical courses, but underlying pathophysiological differences remain unclear. We compared pathological components between RRMS, PPMS, and other inflammatory and neurodegenerative disorders, leveraging soluble biomarkers and post‐mortem ...
Katelijn M. Blok, Romy A. M. Klein Kranenbarg, Kirtana Ananth, Hendrik J. Engelenburg, Aletta van den Bosch, Lucia A. A. Giannini, Janet de Beukelaar, Harro Seelaar, Inge Huitinga, Ari Green, Beatrijs Wokke, Ahmed Abdelhak, Joost Smolders   +12 more
wiley   +1 more source

Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment

Therapeutic Advances in Neurological Disorders, 2015
Background: Fingolimod (FTY) is the first oral medication approved for multiple sclerosis therapy. Until now, little has been known about the effects of FTY withdrawal regarding disease activity and development of tumefactive demyelinating lesions (TDLs),
Simon Faissner, Robert Hoepner, Carsten Lukas, Andrew Chan, Ralf Gold, Gisa Ellrichmann   +5 more
doaj   +1 more source

MS Variants (ORP-38) [PDF]

Neurology Letters, 2023
In this lecture, multiple sclerosis variants will be discussed, which include Solitary Sclerosis, Schilder's disease, Baló's concentric sclerosis, Marburg variant of multiple sclerosis.
Ebrahim Kouchaki
doaj  

A Tumefactive Multiple Sclerosis Case Mimicking a Focal Cerebral Mass

Çukurova Üniversitesi Tıp Fakültesi Dergisi, 2013
Tumefactive multiple sclerosis is a rare demyelinating disease presenting with a focal cerebral mass. Clinically and radiographically, the disease is usually difficult to differentiate from a tumor and abscess.
Olcay Unver, Zehra Isik Hasiloglu, Umut Durak, Serap Uysal   +3 more
doaj  

Fingolimod‐associated Balo's concentric sclerosis in multiple sclerosis: A case report

Clinical Case Reports
Key Clinical Message A report of Balo's concentric sclerosis developed alongside with fingolimod use in a patient with previously diagnosed multiple sclerosis.
Parisa Sharifi, Amir Moradi, Abdorreza Naser Moghadasi   +2 more
doaj   +1 more source

ALEXIA WITHOUT AGRAPHIA IN TUMEFACTIVE MULTIPLE SCLEROSIS: A CASE REPOR

Zdravniški Vestnik, 2009
Background Alexia without agraphia is a rare deficit in which the flow of visual input from the right hemisphere is prevented from entering the language network of the left hemisphere.
Ana Ožura, Alenka Horvat Ledinek, Barbara Starovasnik, Alenka Sever, David B.Vodušek   +4 more
doaj  

ePosters Virtual

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Tumefactive Demyelination Lesions: Report on Three Cases

Acta Neurologica Taiwanica
Purpose: Tumefactive demyelination (TD) lesion and its subtype Balo’s concentric sclerosis (BCS), are rare manifestations of central nervous system demyelinating disease.
Chi-Ju Lin, Shih-Chieh Lin, Kai-Wei Yu, Wen-Yu Ou Yang, Yi-Chung Lee, Yi-Chu Liao   +5 more
doaj   +1 more source